Phylogenetic ctDNA analysis depicts early stage lung cancer evolution.

PubWeight™: 2.54‹?› | Rank: Top 2%

🔗 View Article (PMID 28445469)

Published in Nature on April 26, 2017

Authors

Christopher Abbosh1, Nicolai J Birkbak1,2, Gareth A Wilson1,2, Mariam Jamal-Hanjani1, Tudor Constantin3, Raheleh Salari3, John Le Quesne4, David A Moore4, Selvaraju Veeriah1, Rachel Rosenthal1, Teresa Marafioti1,5, Eser Kirkizlar3, Thomas B K Watkins1,2, Nicholas McGranahan1,2, Sophia Ward1,2,6, Luke Martinson4, Joan Riley4, Francesco Fraioli7, Maise Al Bakir2, Eva Grönroos2, Francisco Zambrana1, Raymondo Endozo7, Wenya Linda Bi8,9, Fiona M Fennessy8,9, Nicole Sponer3, Diana Johnson1, Joanne Laycock1, Seema Shafi1, Justyna Czyzewska-Khan1, Andrew Rowan2, Tim Chambers2,6, Nik Matthews6,10, Samra Turajlic2,11, Crispin Hiley1,2, Siow Ming Lee1,12, Martin D Forster1,12, Tanya Ahmad12, Mary Falzon5, Elaine Borg5, David Lawrence13, Martin Hayward13, Shyam Kolvekar13, Nikolaos Panagiotopoulos13, Sam M Janes1,14,15, Ricky Thakrar14, Asia Ahmed16, Fiona Blackhall17,18, Yvonne Summers18, Dina Hafez3, Ashwini Naik3, Apratim Ganguly3, Stephanie Kareht3, Rajesh Shah19, Leena Joseph20, Anne Marie Quinn20, Phil A Crosbie21, Babu Naidu22,23, Gary Middleton24, Gerald Langman25, Simon Trotter25, Marianne Nicolson26, Hardy Remmen27, Keith Kerr28, Mahendran Chetty29, Lesley Gomersall30, Dean A Fennell4, Apostolos Nakas31, Sridhar Rathinam31, Girija Anand32, Sajid Khan33,34, Peter Russell35, Veni Ezhil36, Babikir Ismail37, Melanie Irvin-Sellers38, Vineet Prakash39, Jason F Lester40, Malgorzata Kornaszewska41, Richard Attanoos42, Haydn Adams43, Helen Davies44, Dahmane Oukrif1, Ayse U Akarca1, John A Hartley45, Helen L Lowe45, Sara Lock46, Natasha Iles47, Harriet Bell47, Yenting Ngai47, Greg Elgar2,6, Zoltan Szallasi48,49,50, Roland F Schwarz51, Javier Herrero52, Aengus Stewart53, Sergio A Quezada54, Karl S Peggs54,55, Peter Van Loo56,57, Caroline Dive1,58, C Jimmy Lin3, Matthew Rabinowitz3, Hugo J W L Aerts8,9,59, Allan Hackshaw47, Jacqui A Shaw4, Bernhard G Zimmermann3, TRACERx consortium, PEACE consortium, Charles Swanton1,2

Author Affiliations

1: Cancer Research UK Lung Cancer Centre of Excellence London and Manchester, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
2: Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
3: Natera Inc., 201 Industrial Road, San Carlos, California 94070, USA.
4: Cancer Studies, University of Leicester, Leicester LE2 7LX, UK.
5: Department of Pathology, University College London Hospitals, 21 University Street, London WC1 6JJ, UK.
6: Advanced Sequencing Facility, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
7: Department of Nuclear Medicine, University College London Hospitals, 235 Euston Road, Fitzrovia, London, NW1 2BU, UK.
8: Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
9: Harvard Medical School, Boston, Massachusetts 02115, USA.
10: Tumour Profiling Unit Genomics Facility, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK.
11: Renal and Skin Units, The Royal Marsden Hospital, London SW3 6JJ, UK.
12: Department of Oncology, University College London Hospitals, 250 Euston Road, London NW1 2BU, UK.
13: Department of Cardiothoracic Surgery, University College London Hospitals, 235 Euston Road, Fitzrovia, London NW1 2BU, UK.
14: Department of Respiratory Medicine, University College London Hospitals, 235 Euston Road, Fitzrovia, London NW1 2BU, UK.
15: Lungs for Living Research Centre, UCL Respiratory, Division of Medicine, Rayne Building, University College London, 5 University Street, London WC1E 6JF, UK.
16: Department of Radiology, University College London Hospitals, 235 Euston Road, Fitzrovia, London NW1 2BU, UK.
17: Institute of Cancer Studies, University of Manchester, Oxford Road, Manchester M13 9PL, UK.
18: The Christie Hospital, Manchester M20 4BX, UK.
19: Department of Cardiothoracic Surgery, University Hospital South Manchester, Manchester M23 9LT, UK.
20: Department of Pathology, University Hospital South Manchester, Manchester M23 9LT, UK.
21: North West Lung Centre, University Hospital South Manchester, Manchester M23 9LT, UK.
22: Department of Thoracic Surgery, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK.
23: Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2TT, UK. University College London Hospitals NHS Foundation Trust, London, UK.
24: Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.
25: Department of Cellular Pathology, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK.
26: Department of Medical Oncology, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK.
27: Department of Cardiothoracic Surgery, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen AB25 2ZD, UK.
28: Department of Pathology, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen AB25 2ZD, UK.
29: Department of Respiratory Medicine, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK.
30: Department of Radiology, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK.
31: Department of Thoracic Surgery, Glenfield Hospital, Leicester LE3 9QP, UK.
32: Department of Radiotherapy, North Middlesex University Hospital, London N18 1QX, UK.
33: Department of Respiratory Medicine, Royal Free Hospital, Pond Street, London NW3 2QG, UK.
34: Department of Respiratory Medicine, Barnet and Chase Farm Hospitals, Wellhouse Lane, Barnet EN5 3DJ, UK.
35: Department of Respiratory Medicine, The Princess Alexandra Hospital, Hamstel Road, Harlow CM20 1QX, UK.
36: Department of Clinical Oncology, St.Luke's Cancer Centre, Royal Surrey County Hospital, Guildford GU2 7XX, UK.
37: Department of Pathology, Ashford and St. Peter's Hospital, Guildford Road, Chertsey, Surrey KT16 0PZ, UK.
38: Department of Respiratory Medicine, Ashford and St. Peter's Hospital, Guildford Road, Chertsey, Surrey KT16 0PZ, UK.
39: Department of Radiology, Ashford and St. Peter's Hospital, Guildford Road, Chertsey, Surrey KT16 0PZ, UK.
40: Department of Clinical Oncology, Velindre Hospital, Cardiff CF14 2TL, UK.
41: Department of Cardiothoracic Surgery, University Hospital of Wales, Cardiff CF14 4XW, UK.
42: Department of Cellular Pathology, University Hospital of Wales and Cardiff University, Heath Park, Cardiff, UK.
43: Department of Radiology, University Hospital Llandough, Cardiff CF64 2XX, UK.
44: Department of Respiratory Medicine, University Hospital Llandough, Cardiff CF64 2XX, UK.
45: University College London Experimental Cancer Medicine Centre GCLP Facility, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
46: Department of Respiratory Medicine, The Whittington Hospital NHS Trust, London, N19 5NF, UK.
47: University College London, Cancer Research UK and UCL Cancer Trials Centre, London W1T 4TJ, UK.
48: Centre for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, 2800 Lyngby, Denmark.
49: Computational Health Informatics Program (CHIP), Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
50: MTA-SE-NAP, Brain Metastasis Research Group, 2nd Department of Pathology, Semmelweis University, 1091 Budapest, Hungary.
51: Berlin Institute for Medical Systems Biology, Max Delbrueck Center for Molecular Medicine, Berlin, Germany.
52: Bill Lyons Informatics Centre, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
53: Department of Bioinformatics and Biostatistics, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
54: Cancer Immunology Unit, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
55: Research Department of Haematology, University College Cancer Institute, London WC1E 6DD, UK.
56: Cancer Genomics Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
57: Department of Human Genetics, University of Leuven, B-3000 Leuven, Belgium.
58: Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.
59: Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215-5450, USA.

Associated clinical trials:

The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study (PEACE) | NCT03004755

ctDNA as a Assisted Diagnosis, Early Intervention and Prognostic Marker for Peritoneal Metastases From Colorectal Cancer | NCT04752930

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (TRAK-ER) | NCT04985266

Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer (Safe-De) | NCT05058183

AssesSment of Early-deteCtion basEd oN liquiD Biopsy in GASTRIC Cancer, ASCEND-Gastric (ASCEND-Gastric) | NCT05224596

Articles cited by this

The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39

Global cancer statistics. CA Cancer J Clin (2011) 185.92

Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86

PEAR: a fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics (2013) 5.61

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98

Cancer Statistics, 2017. CA Cancer J Clin (2017) 4.77

Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76

Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res (2014) 3.50

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med (2015) 3.33

Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med (2017) 2.48

Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res (2000) 2.13

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer (2007) 1.68

Does the cell number 10(9) still really fit one gram of tumor tissue? Cell Cycle (2009) 1.40

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer (2008) 1.38

Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol (2014) 1.34

Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol (2016) 1.32

FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med (2000) 1.26

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun (2015) 1.25

Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol (2016) 1.07

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med (2016) 1.06

Clonality inference in multiple tumor samples using phylogeny. Bioinformatics (2015) 1.05

Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma. J Nucl Med (2015) 0.89

Targeted therapy in NSCLC driven by HER2 insertions. Transl Lung Cancer Res (2014) 0.82

An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET. EJNMMI Res (2016) 0.81

Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas: A brief review. Oncol Lett (2011) 0.79